Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
News-Medical.Net on MSN
Understanding the role of m6A methylation in acute lung injury pathogenesis
Acute lung injury (ALI) is a critical clinical condition characterized by diffuse inflammation of the lung parenchyma and ...
Savara Inc. (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and participate in ...
TipRanks on MSN
Savara Announces $75M Royalty Funding Agreement
Savara Inc. is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Their lead program, MOLBREEVI, is a recombinant human granulocyte-macrophage colony stimulating factor ...
Jefferies, Piper Sandler, and Guggenheim Securities acted as joint book-running managers for the offering. Oppenheimer & Co. acted as the lead manager, and Citizens Capital Markets and H.C. Wainwright ...
Metabolic reprogramming in fibrotic lung diseases involves key metabolites like lactate, succinate, and 2-hydroxyglutarate, ...
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has commenced an underwritten public offering of shares of its ...
9d
Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants
Jefferies, Piper Sandler, and Guggenheim Securities are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as the lead manager, and Citizens Capital Markets and H.C.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback